[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-US2006/270873,2006,A1Locationinpatent:Page/Pagecolumn7
123-41-1
[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2006/9940,2006,A1Locationinpatent:Page/Pagecolumn36-37
[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2006/9940,2006,A1Locationinpatent:Page/Pagecolumn35
[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2006/9940,2006,A1Locationinpatent:Page/Pagecolumn36
[2]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2006/9940,2006,A1Locationinpatent:Page/Pagecolumn36
[1]CurrentPatentAssignee:SYNTAPHARMACEUTICALSCORP.-WO2006/9940,2006,A1Locationinpatent:Page/Pagecolumn32
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
Journal: Cancer research 20121001
Title: The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.
Journal: Free radical biology & medicine 20120515
Title: Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.
Journal: DNA repair 20120501
Title: Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.
Journal: PloS one 20120101
Title: Mitochondrial respiration--an important therapeutic target in melanoma.
Journal: PloS one 20120101
Title: LC-MS/MS and density functional theory study of copper(II) and nickel(II) chelating complexes of elesclomol (a novel anticancer agent).
Journal: Journal of pharmaceutical and biomedical analysis 20110125
Title: Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
Journal: Breast cancer research and treatment 20100601
Title: Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110
Title: Elesclomol induces cancer cell apoptosis through oxidative stress.
Journal: Molecular cancer therapeutics 20080801
Title: Molecule of the month. Elesclomol and obatoclax mesylate.
Journal: Drug news & perspectives 20080301
Title: Reactive oxygen species may have antitumor activity in metastatic melanoma.
Journal: Journal of the National Cancer Institute 20080102
Title: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070115
Title: Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060601
